Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

IGF-1 HumanExplore study findings

What near-adult height data add to pediatric growth research

2 numbered sourcesSource years 2025, 2026

Peptides are short chains of amino acids linked by peptide bonds. Some larger hormones use the same kind of bonds and carry signals that guide tissue growth. Human insulin-like growth factor 1 (IGF-1) contains 70 amino acids. Mecasermin is a recombinant medicine with the same amino-acid sequence. A patient registry examined what happened to height over years in children treated for severe growth failure. [1, 2]

No newer primary report of this exact near-adult-height analysis was identified. The study was first published online in July 2025 and appeared in a February 2026 issue. It described 102 patients who reached near-adult height during or after recombinant human IGF-1 therapy. Near-adult height is a late point in growth, when little additional height is expected. The team examined height in relation to a standard reference and explored factors associated with greater gains. [1]

Children who had started therapy before puberty and had not previously received growth-promoting treatment showed the greatest improvements as a group. The authors also found an association between a lower height score at the start and a greater gain among those patients. The measurements put growth over a year in context with growth accumulated over a much longer period. A faster rate in the first year and a higher near-adult height are related outcomes that can tell different stories. [1]

Registry data describe how people fared in clinical care. The analysis did not randomly assign treatment or when treatment began. It also focused on people who had documented near-adult height by the study cutoff. Reasons that some patients continued or stopped treatment, and incomplete measurements in later years, can influence the reported estimates. There were too few quality-of-life records to address that outcome in the analysis. [1]

The U.S. approval for mecasermin concerns growth failure in defined pediatric patients, including those with severe primary IGF-1 deficiency. The registry adds longer-term information about treated patients. It does not establish that a change in height score predicts an individual's experience or that the results apply to children with a different cause of short stature. [1, 2]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop IGF-1 Human

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.